Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: kerostx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | Buy | Jefferies | |
| 10/24/2024 | Overweight | Cantor Fitzgerald | |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/23/2024 | $96.00 | Buy | Guggenheim |
| 6/25/2024 | $102.00 | Outperform | Oppenheimer |
| 2/21/2024 | Outperform | William Blair | |
| 12/8/2023 | $60.00 | Overweight | Wells Fargo |
| 7/31/2023 | $86.00 | Outperform | Wedbush |
| 7/26/2023 | $65.00 | Buy | BofA Securities |
| 2/14/2023 | Outperform | Cowen |
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13D/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13D/A - Keros Therapeutics, Inc. (0001664710) (Subject)
Oppenheimer initiated coverage on Keros Therapeutics Inc (NASDAQ:KROS), a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Oppenheimer writes, “Keros is developing best-in-class therapeutics that regulate TGF-β signaling to treat hematological and cardiopulmonary diseases. We consider its pipeline one of the more attractive in biotech today, given its disease-modifying potential in indications with considerable unmet need.” Keros’ lead product candidate, KER-050 (elritercept), is being developed for low blood cell counts or cytopenias, i
Oppenheimer analyst Andreas Argyrides initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Outperform rating and announces Price Target of $102.
Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden. Durable clinical responses were associated with improvements in patient-reported measures of fatigue. Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scores.
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which beat the analyst consensus estimate of $(1.34) by 9.7 percent. This is a 3.97 percent increase over losses of $(1.26) per share from the same period last year. The company reported $83.00 thousand in sales this quarter.
Piper Sandler analyst Joseph Catanzaro maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and maintains $105 price target.
10-Q - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
144 - Keros Therapeutics, Inc. (0001664710) (Subject)
144 - Keros Therapeutics, Inc. (0001664710) (Subject)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
Jefferies initiated coverage of Keros Therapeutics with a rating of Buy
Cantor Fitzgerald initiated coverage of Keros Therapeutics with a rating of Overweight
Scotiabank initiated coverage of Keros Therapeutics with a rating of Sector Outperform
Guggenheim initiated coverage of Keros Therapeutics with a rating of Buy and set a new price target of $96.00
Oppenheimer initiated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $102.00
William Blair initiated coverage of Keros Therapeutics with a rating of Outperform
Wells Fargo initiated coverage of Keros Therapeutics with a rating of Overweight and set a new price target of $60.00
Wedbush initiated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $86.00
BofA Securities initiated coverage of Keros Therapeutics with a rating of Buy and set a new price target of $65.00
Cowen initiated coverage of Keros Therapeutics with a rating of Outperform
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that three abstracts will be presented from its hematology program at the 66th American Society of Hematology ("ASH") Annual Meeting and Exposition to be held in person and virtually from December 7 through 10, 2024. Keros will be presenting additional results from its two ongoing Phase 2 clinical trials of elrite
LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi
LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the 2024 Cantor Global Healthcare Conference that will now begin at 8:00 a.m. Eastern time on Thursday, September 19, 2024. A live audio webcast of the fireside chat present
LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the Company has closed screening for the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"). As a result, Keros expects to complete enrollment by the end of September and present topl
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Date and Time: Wednesday, September 4, 2024 at 4:05 p.m. Eastern timeLink: https://cc.webcasts.com/morg007/090424a_
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all programs across our pipeline in the second quarter of 2024, as evidenced by our recent positive regulatory and data updates from the elritercept (KER-050) program," said Jasbir S. Seehra, Ph.D
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced changes to its Board of Directors ("Board") and Executive Committee, effective July 1, 2024. Keros' Board has appointed Jasbir S. Seehra, Ph.D., Chief Executive Officer, as Chair of the Board, effective July 1, 2024. Dr. Seehra will succeed current Chair Carl L. Gordon, Ph.D, C.F.A., who will remain
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigueData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scoresKeros will host a corporate update call and webcast today, June 17, 2024, at 8:00 a.m. ET LEXINGTON, Mass., June 17, 2024 (GLOBE NE
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. Eastern time. "I am pleased to announce that Keros received positive feedback from the U.S. Food and Drug Administration regarding the KER-050 (elritercept) myelodysplastic syndromes ("MDS"
LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. Eastern time. A live audio webcast of the fireside chat presentation will be available at https:/
LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply
LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a
LEXINGTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the appointment of Christopher Rovaldi as Keros' Chief Operating Officer, effective as of February 1, 2022. Mr. Rovaldi previously served as a consultant to Keros. "We are excited to welcome Mr. Rovaldi to the executive team as Chief Operating Officer," said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros. "This addition allows us to benefit
LEXINGTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it appointed Mary Ann Gray, Ph.D., to its Board of Directors. "We are delighted to welcome Dr. Gray to Keros’ Board of Directors,” said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Her deep experience guiding both growing and commercial-stage companies as a board member, coupled with her scientific and financia
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all programs across our pipeline in the second quarter of 2024, as evidenced by our recent positive regulatory and data updates from the elritercept (KER-050) program," said Jasbir S. Seehra, Ph.D
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigueData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scoresKeros will host a corporate update call and webcast today, June 17, 2024, at 8:00 a.m. ET LEXINGTON, Mass., June 17, 2024 (GLOBE NE
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. Eastern time. "I am pleased to announce that Keros received positive feedback from the U.S. Food and Drug Administration regarding the KER-050 (elritercept) myelodysplastic syndromes ("MDS"
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. "Keros remained focused on clinical execution and continued to make strong progress across our pipeline in the first quarter of 2024," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "We look
KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in patient-reported measures of fatigueBiomarker data demonstrate that KER-050 treatment has potential to reduce NT-proBNP a measure of cardiac stressPreliminary findings from ongoing Phase 2 clinical trial in myelofibrosis demonstrate that KER-050 can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit seen through reduction of spleen size and improved symptomsKeros will be hosting a conference call and webcast today, December 11, 2023, at 8
LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS) is re-issuing this press release solely to correct inadvertent typographical errors. The corrected press release reads in its entirety as follows: Keros Therapeutics announces U.S. Food and Drug Administration ("FDA") has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with background therapy in patients with pulmonary arterial hypertension LEXINGTON, Mass., July 24, 2023 – Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization o
Keros Therapeutics announces U.S. Food and Drug Administration ("FDA") has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with background therapy in patients with pulmonary arterial hypertension LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros will host a conference call and webcast to provide an overview of TROPOS,
Keros Therapeutics will be hosting a conference call and webcast today, June 9, 2023, at 8:00 a.m. Eastern time, to provide an update on its hematology franchise. LEXINGTON, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome
LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes ("MDS"), as well as initial data from its ongoing Phase 2 clinical trial of KER-050 in patients with myelofibrosis ("MF") and from its ongoing Phase 2 clinical trial of KER-047 in
Keros Therapeutics will be hosting a conference call and webcast today, June 10, 2022, at 8:00 a.m. Eastern time. LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes ("MDS"), as well as preclinical data on the differentia